SCHEMBL3017906

SCHEMBL3017906

Cc1cccc(-c2csc(N3CCN(S(=O)(=O)c4ccccc4Cl)CC3)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.56
ALDH1A1 P00352 5/20 0.56
LMNA P02545 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
MAPK1 P28482 4/20 0.56
HSD17B10 Q99714 2/20 0.53
RECQL P46063 2/20 0.53
USP2 O75604 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.48
RAB9A P51151 1/20 0.47
FAAH O00519 2/20 0.47
EPHX2 P34913 2/20 0.47
GBA1 P04062 1/20 0.46
HTT P42858 2/20 0.46
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
KDM4E B2RXH2 1/20 0.44
CHRM4 P08173 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011207 0.93 MAPT (0.53) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3009921 0.92 SMN1; SMN2 (0.56) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3015002 0.90 LMNA (0.52) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3013300 0.90 MEN1 (0.52) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3003616 0.89 MAPT (0.56) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3015579 0.89 SMN1; SMN2 (0.62) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3019326 0.88 MAPT (0.59) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3016064 0.88 MAPT (0.50) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3012515 0.88 LMNA (0.68) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3006873 0.88 LMNA (0.52) MAPTALDH1A1LMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.